Aileron Therapeutics, Inc. (ALRN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aileron Therapeutics, Inc. (ALRN) trades at $2.11 with AI Score 44/100 (Grade C). Aileron Therapeutics, Inc. is a clinical-stage oncology company focused on developing chemoprotection therapies. Market cap: $45.72M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for ALRN: ALRN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALRN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ALRN: the 1 perspectives are evenly split.
How is this calculated? →Aileron Therapeutics, Inc. (ALRN) Healthcare & Pipeline Overview
Aileron Therapeutics, Inc. is a clinical-stage biotechnology company specializing in chemoprotection therapies, primarily focused on its lead drug candidate, ALRN-6924. Targeting the treatment of solid tumors, lymphoma, AML, and MDS, Aileron seeks to mitigate chemotherapy's toxic side effects, differentiating itself through innovative peptide-based therapeutics within the competitive oncology landscape.
What Is the Investment Thesis for ALRN?
Aileron Therapeutics' investment thesis hinges on the successful development and commercialization of ALRN-6924, its lead chemoprotection drug candidate. The company's focus on protecting healthy cells during cancer treatment addresses a significant unmet need, potentially improving patient outcomes and quality of life. Key value drivers include positive clinical trial results, regulatory approvals, and strategic partnerships. Upcoming data readouts from ongoing Phase 1 and Phase 2 trials of ALRN-6924 in various cancer indications represent crucial catalysts. However, the company faces risks associated with clinical trial failures, regulatory hurdles, and competition from established cancer therapies. With a market capitalization of $45.72M and a beta of 2.34, Aileron exhibits high volatility, reflecting the inherent risks and potential rewards of investing in a clinical-stage biotechnology company. Successful execution of its clinical development program could drive significant value creation, while setbacks could negatively impact the company's prospects.
Based on FMP financials and quantitative analysis
ALRN Key Highlights
- Aileron Therapeutics is a clinical-stage company focused on chemoprotection oncology.
- Lead drug candidate ALRN-6924 is in Phase 1 and Phase 2 clinical trials for various cancers.
- ALRN-6924 aims to protect healthy cells from chemotherapy-induced damage.
- The company has license agreements with Dana-Farber Cancer Institute and Harvard College.
- Aileron's market capitalization is $0.05 billion with a P/E ratio of -0.64.
Who Are ALRN's Competitors?
ALRN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVR AlloVir, Inc. | $9.81 | +4.14% | $49.48M | 46 |
| BLUE bluebird bio, Inc. | $4.97 | +0.00% | $48.67M | 67 |
| ERYP ERYTECH Pharma S.A. | $0.78 | +1.30% | $47.38M | 51 |
| GRNA GreenLight Biosciences Holdings | $0.30 | -0.03% | $45.43M | 57 |
| KRON Kronos Bio, Inc. | $0.88 | +1.49% | $53.65M | 65 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALRN's Key Strengths?
- Novel chemoprotection approach.
- Lead drug candidate in clinical trials.
- Strong intellectual property portfolio.
- Experienced management team.
What Are ALRN's Weaknesses?
- Clinical-stage company with no approved products.
- Limited financial resources.
- High dependence on ALRN-6924.
- Small number of employees.
What Could Drive ALRN Stock Higher?
- Data readout from Phase 1 trial of ALRN-6924 in solid tumors and lymphoma.
- Data readout from Phase 2a clinical trial of ALRN-6924 in peripheral T-cell lymphoma.
- Data readout from Phase 1 trial of ALRN-6924 in AML and MDS.
- Enrollment and progress in ongoing clinical trials of ALRN-6924.
- Potential for strategic partnerships and collaborations.
What Are the Key Risks for ALRN?
- Financial-distress signal — its Altman Z-Score of -25.83 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from established cancer therapies.
- Patent challenges and intellectual property disputes.
- Limited financial resources and dependence on external funding.
What Are the Growth Opportunities for ALRN?
- Expansion into New Cancer Indications: Aileron has the opportunity to expand the use of ALRN-6924 into additional cancer indications beyond its current clinical trials. The global market for cancer therapeutics is projected to reach trillions of dollars by 2026, providing a significant opportunity for Aileron to capture market share by demonstrating the efficacy and safety of ALRN-6924 in a wider range of cancers. This expansion could involve conducting new clinical trials or partnering with other companies to explore new therapeutic combinations. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Aileron can pursue strategic partnerships and collaborations with other pharmaceutical companies or research institutions to accelerate the development and commercialization of ALRN-6924. Collaborations can provide access to additional resources, expertise, and funding, as well as expand Aileron's market reach. The market for pharmaceutical collaborations is growing, with companies increasingly seeking partnerships to share risks and accelerate innovation. Timeline: Ongoing.
- Regulatory Approvals and Commercialization: Successful completion of clinical trials and regulatory approvals for ALRN-6924 represent a significant growth opportunity for Aileron. Regulatory approval would allow Aileron to commercialize ALRN-6924 and generate revenue from sales of the drug. The market for cancer therapeutics is highly regulated, and obtaining regulatory approval requires demonstrating the safety and efficacy of the drug in clinical trials. Timeline: Dependent on clinical trial outcomes and regulatory review processes.
- Development of Next-Generation Chemoprotection Therapies: Aileron can leverage its expertise in chemoprotection to develop next-generation therapies that address the limitations of existing cancer treatments. This could involve developing new drugs that target different pathways or mechanisms of action, or improving the delivery and efficacy of existing chemoprotection therapies. The market for innovative cancer therapies is growing, driven by the need for more effective and less toxic treatments. Timeline: Long-term.
- Out-licensing or Acquisition: Aileron could pursue an out-licensing or acquisition strategy to generate value for its shareholders. Out-licensing involves granting another company the rights to develop and commercialize ALRN-6924 in exchange for upfront payments, royalties, and milestones. Acquisition involves selling the company to another pharmaceutical company or biotechnology company. The market for pharmaceutical licensing and acquisitions is active, with companies seeking to acquire promising drug candidates and technologies. Timeline: Dependent on market conditions and strategic opportunities.
What Opportunities Does ALRN Have?
- Expansion into new cancer indications.
- Strategic partnerships and collaborations.
- Regulatory approvals and commercialization.
- Development of next-generation therapies.
What Threats Does ALRN Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established therapies.
- Patent challenges.
What Are ALRN's Competitive Advantages?
- Proprietary peptide-based technology platform.
- First-in-class chemoprotection drug candidate (ALRN-6924).
- Strong intellectual property protection.
- Established collaborations with leading research institutions.
What Does ALRN Do?
Aileron Therapeutics, Inc., founded in 2001 and based in Boston, Massachusetts, is a clinical-stage chemoprotection oncology company dedicated to developing and commercializing novel therapies that protect healthy cells from the toxic side effects of cancer treatments. Originally incorporated as Renegade Therapeutics, Inc., the company changed its name to Aileron Therapeutics, Inc. in February 2007. The company's primary focus is on its lead drug candidate, ALRN-6924, a first-in-class peptide that selectively binds to and inhibits the MDM2 and MDMX proteins, which are key regulators of the p53 tumor suppressor protein. By modulating the p53 pathway, ALRN-6924 aims to protect healthy cells from chemotherapy-induced damage while potentially enhancing the efficacy of cancer treatments. Aileron is currently evaluating ALRN-6924 in multiple clinical trials, including Phase 1 trials for solid tumors and lymphoma, a Phase 2a clinical trial for peripheral T-cell lymphoma, and Phase 1 trials for acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS). Additionally, Aileron is exploring the combination of ALRN-6924 with other cancer therapies, such as cytarabine (Ara-C) in patients with MDS and palbociclib in patients with tumors harboring MDM2 amplifications or p53-mutated small cell lung cancer. Aileron has established license agreements with Dana-Farber Cancer Institute and Harvard College, as well as Umicore Precious Metals Chemistry USA, LLC, to support its research and development efforts.
What Products and Services Does ALRN Offer?
- Develops chemoprotection oncology therapies.
- Focuses on protecting healthy cells during cancer treatment.
- Conducts clinical trials for ALRN-6924 in various cancer indications.
- Targets solid tumors, lymphoma, AML, and MDS.
- Seeks to mitigate chemotherapy's toxic side effects.
- Pursues strategic partnerships and collaborations.
How Does ALRN Make Money?
- Develops and patents novel chemoprotection therapies.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approvals from the FDA.
- Commercializes approved therapies directly or through partnerships.
What Industry Does ALRN Operate In?
Aileron Therapeutics operates within the biotechnology industry, specifically targeting the oncology market. The industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The global oncology market is projected to reach trillions of dollars by 2026, driven by an aging population and increasing cancer incidence. Aileron's chemoprotection approach aims to address the limitations of existing cancer therapies by mitigating toxic side effects, potentially improving treatment outcomes and patient quality of life. Competitors like ALVR, BLUE, ERYP, GRNA, and KRON are also developing innovative cancer therapies, highlighting the dynamic and competitive nature of the oncology market.
Who Are ALRN's Key Customers?
- Cancer patients undergoing chemotherapy.
- Oncologists and hematologists.
- Hospitals and cancer centers.
- Pharmaceutical companies (potential partners).
Key Financial Metrics
Its free cash flow yield is -56.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.40 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -157.5%, the inverse of the P/E and a quick read on earnings relative to price.
Aileron Therapeutics, Inc. (ALRN) Valuation Context
Valued at $45.72M, ALRN is classified as a micro-cap stock. Relative to its peer group, ALRN's quantitative score of 44/100 is below the peer average of 57/100.
Company Profile
Aileron Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO James Brian Windsor. ALRN has traded publicly since 2017.
F-Score 1/9Financial Health
Aileron Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -25.83 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Aileron Therapeutics, Inc. revenue of about $69.8M for fiscal 2026, with EPS near $-1.78.
Net buyingInsider Activity
The most recent 12 insider filings for Aileron Therapeutics, Inc. break down as 0 sales and 12 purchases. On net that is roughly 704K shares acquired (about $2.0M) — insiders putting money in tends to read as conviction.
ALRN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Aileron Therapeutics' future, indicating that executives believe in the company's potential.
- Community sentiment has shifted positively, with increased discussions around their innovative therapies, signaling growing investor interest.
- Recent announcements about progress in clinical trials have sparked optimism among investors, highlighting the company's commitment to advancing its pipeline.
- The biotech sector's overall momentum has led to a favorable environment for Aileron, as investors are keen on promising therapeutic developments.
Bear Case
- Concerns about the volatility in the biotech sector may lead to hesitance among investors, particularly given Aileron's past performance.
- Community discussions reveal skepticism about the company's ability to meet regulatory hurdles, which could impact its long-term viability.
- Recent market trends indicate a cautious approach towards smaller biotech firms, as investors prefer established players with proven track records.
- Insider selling activity in the past raises red flags, leading to questions about the company's immediate prospects and potential challenges ahead.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ALRN Latest News
No recent news available for ALRN.
ALRN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALRN.
Price Targets
Wall Street price target analysis for ALRN.
ALRN MoonshotScore
What does this score mean?
The MoonshotScore rates ALRN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: James Brian Windsor
CEO
James Brian Windsor serves as the Chief Executive Officer of Aileron Therapeutics, Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on oncology drug development and commercialization. Prior to joining Aileron, Mr. Windsor held leadership positions at various companies, where he was responsible for overseeing clinical trials, regulatory submissions, and product launches. He has a proven track record of driving strategic growth and building successful teams.
Track Record: Under James Brian Windsor's leadership, Aileron Therapeutics has advanced its lead drug candidate, ALRN-6924, through multiple clinical trials in various cancer indications. He has focused on securing strategic partnerships and collaborations to support the company's research and development efforts. His tenure has been marked by a commitment to innovation and a focus on addressing the unmet needs of cancer patients.
Aileron Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What does Aileron Therapeutics, Inc. do?
Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing chemoprotection therapies for cancer patients. Its lead drug candidate, ALRN-6924, is designed to protect healthy cells from the toxic side effects of chemotherapy, potentially improving patient outcomes and quality of life. The company is currently evaluating ALRN-6924 in multiple clinical trials across various cancer indications, including solid tumors, lymphoma, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS). Aileron's innovative approach aims to address a significant unmet need in cancer treatment.
What do analysts say about ALRN stock?
Analyst coverage of Aileron Therapeutics (ALRN) is currently limited, reflecting the company's early stage and speculative nature. Key valuation metrics are influenced by the potential success of ALRN-6924 in clinical trials and its ability to secure regulatory approvals. Growth considerations revolve around the expansion of ALRN-6924 into new cancer indications and the formation of strategic partnerships. The stock's high beta of 2.34 indicates significant volatility, reflecting the inherent risks and potential rewards associated with investing in a clinical-stage biotechnology company. Investors should conduct thorough due diligence and consider their risk tolerance before investing in ALRN.
What are the main risks for ALRN?
Aileron Therapeutics faces several key risks inherent to the biotechnology industry and its specific business model. Clinical trial failures represent a significant risk, as the company's success hinges on the positive results of its ongoing clinical trials for ALRN-6924. Regulatory hurdles and delays in obtaining approvals from the FDA could also impact the company's timeline and financial prospects. Competition from established cancer therapies and other emerging treatments poses a threat to Aileron's market share. Additionally, the company faces risks associated with patent challenges, intellectual property disputes, and its limited financial resources.
How does Aileron Therapeutics, Inc. navigate regulatory approval processes?
Aileron Therapeutics navigates regulatory approval processes primarily through adherence to FDA guidelines and regulations. The company meticulously designs and executes clinical trials to demonstrate the safety and efficacy of ALRN-6924. Aileron maintains ongoing communication with regulatory agencies, including the FDA, to ensure compliance and address any concerns. The company's regulatory strategy involves compiling comprehensive data packages for submission to regulatory authorities, including preclinical data, clinical trial results, and manufacturing information. Aileron's success in obtaining regulatory approvals depends on the strength of its clinical data and its ability to demonstrate a favorable benefit-risk profile for ALRN-6924.
What is Aileron Therapeutics, Inc.'s drug pipeline status?
Aileron Therapeutics' drug pipeline is centered around its lead drug candidate, ALRN-6924, which is currently in various stages of clinical development. ALRN-6924 is being evaluated in Phase 1 trials for solid tumors and lymphoma, a Phase 2a clinical trial for peripheral T-cell lymphoma, and Phase 1 trials for acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS). The company is also exploring the combination of ALRN-6924 with other cancer therapies, such as cytarabine (Ara-C) and palbociclib. Upcoming catalysts include data readouts from ongoing clinical trials, which will provide insights into the safety and efficacy of ALRN-6924 in different cancer indications. The company's pipeline is focused on chemoprotection therapies, aiming to protect healthy cells from the toxic side effects of cancer treatments.
What are the key factors to evaluate for ALRN?
Aileron Therapeutics, Inc. (ALRN) holds an AI score of 44/100 (low). Not financial advice.
How frequently does ALRN data refresh on this page?
ALRN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ALRN's recent stock price performance?
Aileron Therapeutics, Inc. (ALRN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel chemoprotection approach. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis pending for ALRN.